1. Home
  2. VLTO vs ROIV Comparison

VLTO vs ROIV Comparison

Compare VLTO & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Veralto Corp

VLTO

Veralto Corp

N/A

Current Price

$117.17

Market Cap

28.8B

Sector

Industrials

ML Signal

N/A

Logo Roivant Sciences Ltd.

ROIV

Roivant Sciences Ltd.

N/A

Current Price

$38.91

Market Cap

28.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VLTO
ROIV
Founded
2023
2014
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Electrical Products
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
28.8B
28.7B
IPO Year
2023
2021

Fundamental Metrics

Financial Performance
Metric
VLTO
ROIV
Price
$117.17
$38.91
Analyst Decision
Buy
Strong Buy
Analyst Count
17
13
Target Price
★ $124.63
$50.82
AVG Volume (30 Days)
1.8M
★ 7.1M
Earning Date
10-29-2026
11-09-2026
Dividend Yield
★ 0.45%
N/A
EPS Growth
★ 12.57
N/A
EPS
★ 3.03
N/A
Revenue
★ $5,503,000,000.00
$8,260,000.00
Revenue This Year
$7.96
$1,870.25
Revenue Next Year
$5.25
$271.46
P/E Ratio
$38.31
★ N/A
Revenue Growth
★ 5.97
N/A
52 Week Low
$80.03
$19.96
52 Week High
$120.35
$42.50

Technical Indicators

Market Signals
Indicator
VLTO
ROIV
Relative Strength Index (RSI) 66.09 54.07
Support Level $94.05 $33.11
Resistance Level N/A $42.37
Average True Range (ATR) 2.41 1.55
MACD -0.50 -0.07
Stochastic Oscillator 57.46 49.40

Price Performance

Historical Comparison
VLTO
ROIV

About VLTO Veralto Corp

Veralto is a diversified industrial firm organized into two segments. The water quality segment offers water analytics and water treatment solutions, while the product quality and innovation segment offers coding, packaging, and color solutions for consumer packaged goods and pharmaceuticals. Headquartered in Waltham, Massachusetts, the company has around 17,000 employees. Veralto generated approximately $5.5 billion in revenue in 2025.

About ROIV Roivant Sciences Ltd.

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

Share on Social Networks: